Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with R-CHOP or G-CHOP in B-cell non-Hodgkin lymphoma and untreated DLBCL
NL-OMON45171Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoints: Incidence and nature of dose-limiting toxicities, Venetoclax AUC and 12 more. Started Sep 2014; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON45171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45171.